The Trillion-Dollar Drug

How a diabetes medication became the most important drug in decades

$150B
Projected GLP-1 market by 2030

Bigger than the entire global video game industry. One drug class.

LLYNYSE
Eli Lilly and Company

Pharma giant leading the GLP-1 revolution — Mounjaro, Zepbound

$1064.15
+118138.9% since 1972
Revenue (TTM)
How much money came in the door over the past year. Think of it as total sales before paying any bills.
$40.9B
+27.4%
Net Income (TTM)
What's left after paying everyone—employees, suppliers, taxes, everything. This is the actual profit.
$10.4B
+52.8%
Gross Margin
For every dollar of sales, how much is left after making the product? Higher is better—more room for profit.
82.5%
EPS (TTM)
If you owned one share, this is your slice of the profit. Bigger number = more earnings for each share you hold.
$11.55
+52.6%

Financial Performance

Tirzepatide (Mounjaro/Zepbound) revenue could exceed $25B annually. Gross margins above 80%. Manufacturing capacity is the only bottleneck to even faster growth.

Revenue

Money coming in the door each quarter—total sales before paying any bills.
$11.4B
+124.8%

Net Income

What's left after paying everyone. This is the real profit the company keeps.
$3.0B
+190.5%

Earnings Per Share

Your slice of the profit for each share you own. Bigger = better.
$3.37
+209.2%

Margins

How much profit is made on each dollar of sales. Higher margins = more efficient business.

Profitability over time

Gross
82.5%
Operating
33.0%

The GLP-1 Revolution

From diabetes treatment to weight loss phenomenon — Mounjaro and Zepbound are reshaping healthcare

GLP-1 Revenue

Mounjaro + Zepbound revenue (billions)

GLP-1 Revenue
$17B

GLP-1 Share of Revenue

How much of Lilly depends on these drugs

Share
39.0%

Enjoyed the Eli Lilly and Company breakdown?

Get the next one in your inbox.

About Eli Lilly and Company

Eli Lilly is a global pharmaceutical company founded in 1876. Known for pioneering insulin production, Lilly now leads the GLP-1 revolution with Mounjaro and Zepbound, becoming the world's most valuable pharmaceutical company by market cap.

HealthcarePharmaceuticals

Data Sources

Price Data: Yahoo FinanceFinancials: Eli Lilly and Company SEC Filings